Sigilon Therapeutics logo
Sigilon Therapeutics SGTX
$ 22.47 0.0%

Quarterly report 2023-Q2
added 08-07-2023

report update icon

Sigilon Therapeutics Balance Sheet 2011-2024 | SGTX

Annual Balance Sheet Sigilon Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-25.6 M -83.9 M -177 M -51 M -59.1 M - - - - - - -

Long Term Debt

12 M 18.4 M 19.8 M 14.9 M 4.29 M - - - - - - -

Long Term Debt Current

4.48 M 4.84 M - - - - - - - - - -

Total Non Current Liabilities

- - 31.9 M 128 M 74.6 M - - - - - - -

Total Current Liabilities

31 M 34.9 M - - - - - - - - - -

Total Liabilities

48.1 M 67.2 M 78.9 M 168 M 104 M - - - - - - -

Deferred Revenue

- - 31.8 M 29.1 M 24.7 M - - - - - - -

Retained Earnings

-257 M -213 M -136 M -81.3 M -37.4 M - - - - - - -

Total Assets

87.3 M 144 M 225 M 90.4 M 67.7 M - - - - - - -

Cash and Cash Equivalents

42.1 M 107 M 203 M - - - - - - - - -

Book Value

39.1 M 77.2 M 146 M -77.8 M -36.1 M - - - - - - -

Total Shareholders Equity

39.1 M 77.2 M 146 M - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Sigilon Therapeutics

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.86 M 10.4 M 12 M 13.6 M - 16.8 M 18.4 M 20 M 20 M 20 M 19.8 M 20 M 20 M 20 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

28.1 M 43.3 M 48.1 M 50.2 M - 61.6 M 67.2 M 70.5 M 75.1 M 74.4 M 78.9 M 78.9 M 78.9 M 78.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-272 M -264 M -257 M -250 M - -227 M -213 M -195 M -175 M -155 M -136 M -136 M -136 M -136 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

55.6 M 76.6 M 87.3 M 94.6 M - 126 M 144 M 164 M 186 M 203 M 225 M 225 M 225 M 225 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

19.6 M 41.3 M 42.1 M 32.9 M 35.9 M 161 M 107 M 142 M 162 M 179 M 202 M 202 M 202 M 202 M 76.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

27.4 M 33.3 M 39.1 M 44.4 M - 64.6 M 77.2 M 93.3 M 111 M 129 M 146 M 146 M 146 M 146 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

27.4 M 33.3 M 39.1 M 44.4 M 51.8 M 64.6 M 77.2 M 93.3 M 111 M 129 M 146 M 146 M 146 M 146 M -77.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency